Zurich Cantonal Bank’s Solid Biosciences SLDB Stock Holding History

Zurich Cantonal Bank’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-569	Closed	-$20K	–	2586
2020 Q1	$20K	Buy	+569	New	+$28.2K	﹤0.01%	2349

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Zurich Cantonal Bank's SLDB Position: Q2 2020 in Review

Zurich Cantonal Bank sold out of Solid Biosciences (SLDB) in Q2 2020, closing a stake of 569 shares — an estimated $20K sold.

Zurich Cantonal Bank first reported a position in SLDB in Q1 2020 and held it in 1 quarter. The position peaked at $20K in Q1 2020. 66 funds tracked by Wall St. Rank hold SLDB as of Q2 2020.

Zurich Cantonal Bank reported no remaining Solid Biosciences position as of Q2 2020 after selling out during the quarter.
Zurich Cantonal Bank sold 569 Solid Biosciences shares in Q2 2020, an estimated $20K.
Zurich Cantonal Bank first reported a position in Solid Biosciences in Q1 2020 and held it in 1 quarter.
Zurich Cantonal Bank's Solid Biosciences position peaked at $20K in Q1 2020.
66 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2020.

Based on Zurich Cantonal Bank's 13F filing for Q2 2020, filed 28 Jul 2020.